Results 81 to 90 of about 43,876 (313)

Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect

Journal of Pharmacological Sciences, 2019
Oxaliplatin induces severe peripheral neuropathy. The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models.
Takehiro Kawashiri, Shiori Shimizu, Nao Shigematsu, Daisuke Kobayashi, Takao Shimazoe   +4 more
doaj  

Design, Synthesis, Biological Evaluation, and In Silico Study of Tetrahydropyridines as Prospective Monoamine Oxidase Inhibitors

ChemistryOpen, EarlyView.
This work investigates the selective inhibition of MAO enzymes by varying the substitution of electron‐withdrawing and donating groups on the phenyl rings of tetrahydropyridines (4 a–4 o). Compounds 4 l and 4 n exhibit promising IC50 values of 0.40±0.05 and 1.01±0.03 μM against MAO‐A and MAO‐B, respectively.
Obaid ur Rehman Khan, Bilal Ahmad Khan, Syeda Shamila Hamdani, Saquib Jalil, Peter A. Sidhom, Khalid Elfaki Ibrahim, Tarad Abalkhail, Jamshed Iqbal, Hatem Tallima, Tamer Shoeib, Mahmoud A. A. Ibrahim   +10 more
wiley   +1 more source

Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents. [PDF]

, 2000
Acetylcholinesterase inhibitors (ChEIs) enhance neuronal transmission by increasing the availability of acetylcholine in muscarinic and nicotinic receptors.
A Grob, BJ Carroll, BJ Steinberg, CH Dyck van, D Kaufer, DE Giles, DJ Safer, DS Geldmacher, DS Janowsky, DS Janowsky, DS Janowsky, DS Janowsky, DW Rowntree, EF Willoughby, JC Morris, JL Cummings, JL Cummings, JM Cooney, JM Cooney, KL Davis, KL Lanctot, LJ Thal, M Rosler, MA Raskind, MA Raskind, MA Raskind, MB Bowers, MF Weiner, MS Mega, MS Mega, N Sitaram, PJ Goodnick, PN Tariot, PS Kishnani, RE Becker, RT Rubin, SC Risch, SP Hoopes, SP Wengel, SS Leong, T Burt, Tal Burt, WJ Burke, YM Greene   +43 more
core   +1 more source

SGLT2 Inhibition by Enavogliflozin Significantly Reduces Aβ Pathology and Restores Cognitive Function via Upregulation of Microglial AMPK Signaling in 5XFAD Mouse Model of Alzheimer's Disease

Aging Cell, EarlyView.
SGLT2 inhibition with Enavogliflozin significantly improves cognitive function and reduces Aβ pathology in the 5XFAD mouse model of Alzheimer's disease. Through AMPK activation, Enavogliflozin enhances microglial mitochondrial function and Aβ phagocytosis while reducing neuroinflammation.
Jihui Han, Jaehoon Song, Eun Sun Jung, Ji Won Choi, Hye Young Ji, Inhee Mook‐Jung   +5 more
wiley   +1 more source

Hyperhidrosis: don't sweat it

Internal Medicine Journal, EarlyView.
Abstract Hyperhidrosis is an under‐reported and under‐treated condition that causes significant patient morbidity. Secondary causes require consideration, but the vast majority of cases are idiopathic. The condition is encountered by a range of clinicians, including neurologists, dermatologists and endocrinologists, and it pays to be familiar with the ...
Mitchell J. Lycett, Karl Ng
wiley   +1 more source

Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease [PDF]

, 2015
AIMS: To identify factors predicting improvement/stabilization on the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and investigate whether early treatment responses can predict long-term outcomes, during a ...
Farlow, Martin R., Islam, M. Zahur, Meng, Xiangyi, Sadowsky, Carl H., Velting, Drew M.   +4 more
core   +1 more source

The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Systematic Review and Meta-Analysis

Dementia and Geriatric Cognitive Disorders Extra, 2011
Background/Aims: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer’s disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared ...
I.A. Lockhart, M.E. Orme, S.A. Mitchell
doaj   +1 more source

Assessing the Content of Goals of Care Documentation for Hospitalized Patients With Alzheimer's Disease and Related Dementias

Journal of the American Geriatrics Society, EarlyView.
Documented Patient Values and Preferences and Attendance at Goals of Care Conversations. AD/ADRD—Alzheimer's disease and related dementias. ABSTRACT Background Goals of care (GOC) conversations are an evidence‐based practice that help clarify and align patient values and preferences for medical care with treatment options.
Gina Piscitello, Jennifer Lingler, Katherine Ramos, Yael Schenker, Robert M. Arnold, Jane Schell   +5 more
wiley   +1 more source

Applications of neuroimaging to disease-modification trials in Alzheimer's disease. [PDF]

, 2009
Critical to development of new therapies for Alzheimer's disease (AD) is the ability to detect clinical or pathological change over time. Clinical outcome measures typically used in therapeutic trials have unfortunately proven to be relatively variable ...
Aisen, Paul S, Alzheimer's Disease Neuroimaging Initiative, Brewer, James B, Chen, Kewei, Donohue, Michael, Fleisher, Adam S   +5 more
core   +2 more sources

Obsessive–compulsive disorder induced by donepezil in a patient with Alzheimer's disease

PCN Reports
Background Donepezil, an acetylcholinesterase inhibitor commonly used to treat Alzheimer's disease (AD), is generally well tolerated. There have been no previous reports on donepezil‐induced obsessive–compulsive disorder (OCD).
Kohei Echizen, Daisuke Hirose
doaj   +1 more source